Furthermore, podoplanin‐CLEC2 interaction contributes to venous thrombosis (Suzuki‐Inoue, 2017), suggesting blockade of podoplanin‐mediated inflammation by CLEC2.Fc may be able to reduce the risk of vascular microthrombosis in COVID‐19 patients. This evidence concerns the gene CLEC1B and Venous thrombosis.